We propose that intracellular IGF-1R may serve as a putative biomarker for aggressive cancers, and that therapeutic approaches targeting both ITGB1 and IGF-1R may increase IGF-1R cell surface presence to enhance therapeutic efficacy of cell surface-targeted anti-IGF-1R monoclonal antibodies. This evidence concerns the gene ITGB1 and cancer.